Stable glucose control remains central to managing type 2 diabetes. A new study published in the Journal of Diabetology highlights that basal insulin therapy offers better glycemic stability than premixed regimens when assessed through continuous glucose monitoring (CGM).

The retrospective cohort included 56 adults with type 2 diabetes who were treated with either basal or premixed insulin. The primary endpoint, time in range (TIR), was significantly higher in the basal insulin group (74 ± 16%) compared with the premixed group (60 ± 22%; P < 0.05). Likewise, time above range (TAR), reflecting periods of hyperglycemia, was notably lower with basal insulin (25 ± 17% vs. 37 ± 23%; P < 0.05).

There were no significant differences in time below range (TBR) or coefficient of variation, suggesting comparable safety profiles. These findings reinforce basal insulin as an effective strategy for achieving consistent glucose stability and reducing hyperglycemia risk in adults with type 2 diabetes.